Novartis Spinning Out 2 Phase IIb-Ready Drugs To PureTech Health For An Equity Stake
March 24, 2017 at 14:10 PM EDT
Novartis is spinning out a pair of Phase IIb-ready drugs to Boston-based start-up PureTech Health, setting up a subsidiary called resTORbio which it will now fund, in tranches, with $15 million.
